Rutgers Cancer Institute of New Jersey Clinical Leader Recognized as Fellow of the American Society of Radiation Oncology

Dr. Salma Jabbour has been named a Fellow of the American Society of Radiation Oncology (FASTRO). This distinction honors individuals who have made significant contributions to the society and to the field of radiation oncology through research, education, patient care and service to the field.

Protecting your Heart Before, During and After Cancer Treatment

Therapies such as chemotherapy, radiotherapy, immunotherapy and other novel targeted treatments that are used to combat many cancers have the potential to contribute to cardiac toxicity. Rutgers Cancer Institute expert sheds light on the field of Cardo-Oncology, which focuses on the prevention and treatment of cardiac-related issues in cancer patients.

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health Leader Recognized as NJBIZ 2021 Healthcare Hero

Rutgers Cancer Institute of New Jersey Director Steven K. Libutti, MD, FACS, who is also senior vice president of oncology services at RWJBarnabas Health and vice chancellor for cancer programs for Rutgers Biomedical and Health Sciences, has been named by the business journal NJBIZ as a 2021 Healthcare Hero in the healthcare professional category.

Phage Display-Based Gene Delivery: A Viable Platform Technology for COVID-19 Vaccine Design and Development

Researchers at Rutgers Cancer Institute of New Jersey, Rutgers New Jersey Medical School (NJMS) and the Center for Theoretical Biological Physics (CTBP) at Rice University in Houston, Texas, have demonstrated that a technology with favorable biological attributes known as phage display could be a viable platform for the development of new vaccines to protect against COVID-19.

Experts from Rutgers Cancer Institute of New Jersey Comment on Lifestyle Changes for Cancer Prevention

New Brunswick, N.J., June 28, 2021 – According to the American Cancer Society, cancer is the second leading cause of death among Americans. Researchers believe that one way to decrease the risk of developing cancer is adopting a healthy lifestyle.…

RWJBarnabas Health and Rutgers Cancer Institute of New Jersey Break Ground on Jack & Sheryl Morris Cancer Center

RWJBarnabas Health and Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center, in partnership with the New Brunswick Development Corporation (DEVCO), broke ground on the state’s first freestanding cancer hospital.

Pride, Progress and Breaking down Barriers: LGBTQ+ Cancer Concerns

A person with cancer who identifies as lesbian, gay, bisexual, transgender or non-binary may have unique concerns about communicating with their cancer care team, navigating the healthcare system and coping with their diagnosis. An expert from Rutgers Cancer Institute calls attention to the healthcare challenges and barriers faced by this community during Pride Month and explains how health care professionals are becoming better allies.

Identifying Potential Treatment for Triple Negative Breast Cancer

Researchers at Rutgers Cancer Institute of New Jersey and Rutgers New Jersey Medical School (NJMS) recently discovered a phage display-based approach to halt tumor growth that could be used to treat triple-negative breast cancer – considered the most aggressive type of breast cancer. The findings were published online in the scientific journal eLife.

The Unique Role of the Oncology Nurse: Lifelong Learning, Healing and Helping

Oncology nursing is a unique specialty that requires specific knowledge of the biological and psychosocial dimensions of cancer and its effects on individuals and families. Oncology nurse at Rutgers Cancer Institute of New Jersey shares more on the role of oncology nurses and the importance of the oncology nurse certification.

The Greatest Gift for Mom: Health and Wellness

Now more than ever, we are reminded that health and wellness should always be a top priority. National Women’s Health Month and Mother’s Day, both celebrated in May, are important reminders that women can take control of their health by making feasible lifestyle choices and focusing on preventive care to lower the risk of certain cancers.

What is Bladder Cancer?

The bladder, a part of the urinary system, is a hollow organ in the pelvis with the primary function of storing and then eliminating urine that drains into it from the kidney. Cancer of the bladder develops when abnormal cells in the bladder start to grow out of control. Rutgers Cancer Institute expert explains what you need to know.

Rutgers Cancer Institute of New Jersey Experts Available for Comment on Research Topics during National Cancer Research Month

New Brunswick, N.J., April 29, 2021 – Many years of research devoted to cancer has led to valuable insight and life-saving measures. To highlight the importance of lifesaving research to the millions of people around the world impacted by cancer,…

Experts from Rutgers Cancer Institute of New Jersey Comment on Skin Cancer and Sun Protection

New Brunswick, N.J., April 29, 2021 – According to the National Cancer Institute (NCI), skin cancer is the most common type of cancer. While we all want to enjoy the outdoors, increased exposure to ultraviolet (UV) rays from the sun…

Tanning Beds and Skin Cancer: Heeding the Call to Action

Public health officials and researchers have become increasingly concerned about the health risks posed by indoor tanning. Researchers at Rutgers Cancer Institute of New Jersey recently addressed the importance of increasing efforts to limit indoor tanning among minors in a viewpoint paper published in the April 28 2021 online edition of JAMA Dermatology.

Rutgers Cancer Institute of New Jersey Leader Elected as a Member to the National Academy of Sciences

Rutgers Cancer Institute of New Jersey Deputy Director, Chief Scientific Officer, and Associate Director for Basic Research Eileen White, PhD, has been elected to the National Academy of Sciences (NAS). She is among 120 members elected this year in recognition of their distinguished and continuing achievements in original research.

$9 Million Contract from National Cancer Institute Awarded for NJ State Cancer Registry

The New Jersey State Cancer Registry (NJSCR), under the direction of the State Department of Health in partnership with Rutgers Cancer Institute of New Jersey, has been awarded a seven-year, $9,085,109 contract (75N91021D00009) from the National Cancer Institute (NCI) to support core infrastructure and research activities as part of the Surveillance, Epidemiology, and End Results (SEER) Program, the most authoritative source of information on cancer incidence and survival in the United States. The funding will support ongoing cancer surveillance activities at the NJSCR, as well as support enhancements to New Jersey’s electronic reporting systems such as electronic pathology and medical claims data transmissions.

Rutgers Cancer Institute of New Jersey Clinical Leader Recognized as Fellow of the American Society of Clinical Oncology

Rutgers Cancer Institute of New Jersey Associate Chief of Urology and Urologic Oncology and Director of the Kidney Cancer Program Eric A. Singer, MD, MA, MS, FACS, has been named a Fellow of the American Society of Clinical Oncology (FASCO). This distinction honors members for their extraordinary volunteer service and dedication to the American Society of Clinical Oncology (ASCO).

Rutgers Cancer Institute of New Jersey Awarded $1.3M for Cancer Metabolism and Growth Research Program

Rutgers Cancer Institute has received a $1.3 million, five-year grant from the National Cancer Institute to support the Cancer Metabolism and Growth and Tumor Host Interactions Training Program which will provide postdoctoral candidates the highest quality training and research experience.

Exploring PD-L1 Expression in Malignant Peritoneal Mesothelioma

In a recent study from Rutgers Cancer Institute of New Jersey, researchers tested whether or not mesothelioma cancer cells express high amounts of PD-L1, a protein that is abundantly present on some types of cancer cells. The PD-L1 protein is an inhibitory molecule that binds to the PD-1 receptor on T-cells, which are cells known to have the ability to recognize and destroy cancer cells in the body. Results of the work are being shared as a poster presentation at the Society of Surgical Oncology 2021 International Conference on Surgical Cancer Care virtual meeting.

Exploring Amino Acids Signaling as Intervention for Diabetes and Pancreatic Cancers

Researchers from Rutgers Cancer Institute of New Jersey previously identified a small protein called Rab1A that regulates amino acid signaling. In a recent study, researchers explored the physiological role of Rab1A in mammals using mice though a technique in which one of an organism’s genes is made inoperative, known as genetic knockout.

Exploring Mutational Signatures Associated with Exposure to Carcinogenic Microplastic Compounds

According to the World Health Organization (WHO), plastic products and their chemical derivatives present in the environment present public health concerns, including elevated risk of cancer. Researchers from Rutgers Cancer Institute of New Jersey explored to what extent common components in microplastic pollutants cause DNA damage in human cells.

Negligible Detection of SARS-CoV2 found in Environmental Surface Testing of Hematology/Oncology Inpatient and Outpatient Settings

Researchers from Rutgers Cancer Institute of New Jersey evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility. The study, published in Cancer, revealed extremely low detection of SARS-CoV-2 on environmental surfaces across multiple outpatient and inpatient oncology areas, including an active COVID-19 floor.

Rutgers University Cancer Prevention Researcher and Leader named President-Elect of American Society of Preventative Oncology

Anita Kinney, PhD, director of the Center for Cancer Health Equity at Rutgers School of Public Health and Rutgers Cancer Institute of New Jersey, has been elected as the 2021 president-elect of the American Society of Preventative Oncology (ASPO), a multi-disciplinary society that is committed to serving as an advocate for cancer prevention and control research. In this role, she will serve a two-year term prior to serving as president of the society.

Mason Scientists and Rutgers Cancer Institute of New Jersey Collaboration Receives U.S. Army’s Breakthrough Award to Better Inform HER2 Breast Cancer Treatment

A Rutgers Cancer Institute of New Jersey and George Mason University collaboration received the U.S. Army’s Breast Cancer Research Program (BCRP) Breakthrough Award to quickly confirm if an identified HER2 biomarker can indicate success likelihood of personalized breast cancer treatments.

Exploring Impact of Surgery Delays for Clinical Renal Cell Carcinoma Patients during the COVID-19 Pandemic

During the peak of the COVID-19 pandemic, several elective surgeries for renal cell carcinoma, the most common type of kidney cancer, were delayed with unknown impact on outcomes for patients. Researchers at Rutgers Cancer Institute of New Jersey explored the impact of surgery delays for these patients throughout the United States by utilizing the National Cancer Database to explore outcomes of patients who underwent surgery up to and after three months post diagnosis.

Gynecologic Oncology Leader Named at New Jersey’s Only NCI-designated Comprehensive Cancer Center

Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital (RWJUH), a RWJBarnabas Health facility, have named James K. Aikins, Jr., MD, FACOG, FACS chief of gynecologic oncology at Rutgers Cancer Institute and chief of gynecologic oncology services at RWJUH, New Jersey’s largest academic medical center.

Validation of Novel Prognostic Index May Better Inform Burkitt Lymphoma Treatment

Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health, today announced the publication of research that has identified and validated the novel Burkitt Lymphoma International Prognostic Index (BL-IPI) in patients with this rare, high-grade B-cell lymphoma that is often studied in trials with small sample sizes. This research has been published in the January 2021 online issue of Journal of Clinical Oncology.

First Patient Recently Treated with New Non-Surgical Therapy for Urothelial Cancer at Rutgers Cancer Institute

Upper tract urothelial cancer (UTUC) is a subset of urothelial cancer that is found in the renal pelvis or the ureter, part of the genitourinary tract. Surgery has remained the mainstay of treatment for this type of cancer, until last year, when the U.S. Food and Drug Administration (FDA) approved mitomycin gel as the first non-surgical therapy option to treat this type of cancer. Rutgers Cancer Institute of New Jersey has recently treated its first UTUC patient with this new therapy.

Research Leader Named to Rutgers Cancer Institute from National Cancer Institute to Build World-Class Cancer Immunology and Immunotherapy Programs

Research Leader Christian Hinrichs, MD, has been named Chief of the Section of Cancer Immunotherapy and Co-Director of the Cancer Immunology and Metabolism Center of Excellence at Rutgers Cancer Institute of New Jersey,

Rutgers Cancer Institute of New Jersey Receives $25 Million Gift for Cancer Immunology and Metabolism Center of Excellence

A $25 million transformational gift given to Rutgers Cancer Institute will provide critical support for the Cancer Immunology and Metabolism Center of Excellence to help scientists better understand the human immune response to cancer and ultimately develop the foundation for new treatments or make existing therapies more effective.

Safely Donate Blood This Winter

With the added concern of COVID-19 safety, there will be drop in the donation of critically needed blood throughout the United States, which is typically low during the winter months. Expert from Rutgers Cancer Institute of New Jersey urges giving the gift of life by donating blood.

More Joy, Less Stress: Coping With Cancer through the Holiday Season

The holiday season can be challenging for those impacted by cancer. This time may be especially demanding and draining, creating mixed emotions and added stress due to the COVID-19 pandemic. Expert from Rutgers Cancer Institute of New Jersey provides some strategies to consider for less stress this holiday season.

Rutgers Cancer Institute of New Jersey Experts Available for Comment on General Breast Cancer Topics During Virtual San Antonio Breast Cancer Symposium (SABCS)

New Brunswick, N.J., December 7, 2020 – The San Antonio Breast Cancer Symposium (SABCS) provides an opportunity for basic, translational and clinical cancer research professionals to experience and discuss the most current research and advances in the field of breast…

Examining Clostridium Difficile Infection in Blood and Marrow Transplant and Leukemic Patients

Members of the Hematologic Malignancies Program at Rutgers Cancer Institute of New Jersey examined the utilization of a low dose of oral vancomycin, a drug used at higher doses to treat established Clostridium difficile infection (CDI), as a way to prevent CDI in blood and bone marrow transplant (BMT) patients.

Analyzing Outcomes of Older Patients with Primary Central Nervous System Lymphoma

Older individuals are at an increased risk of developing primary central nervous system lymphoma (PCNSL). In a retrospective study of patients with newly diagnosed PCNSL, researchers at Rutgers Cancer Institute of New Jersey and colleagues used geriatric assessments to analyze detailed characteristics, treatment, and outcomes in patients across 17 academic centers.

Environmental Surface Testing in Inpatient and Outpatient Hematology/Oncology Settings Shows Negligible Detection of SARS-CoV2

Researchers from Rutgers Cancer Institute of New Jersey evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility. The study revealed extremely low detection of SARS-CoV-2 on environmental surfaces across multiple outpatient and inpatient oncology areas, including an active COVID-19 floor.

Exploration of Genomic Ancestry in B-Cell Malignancies Identifies Multiple Important Genomic Differences

Investigators from Foundation Medicine, Inc. and Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center, examined genomic ancestry in BCL subtypes applying genomic ancestry prediction methodology to comprehensive genomic profiling data and found multiple genomic differences. Results of the study will be shared at the virtual American Society of Hematology Annual Meeting.

Rutgers Cancer Institute of New Jersey to Present Expansive New Hematology Data at the 62nd ASH Annual Meeting and Exposition

The American Society of Hematology (ASH), is the world’s largest professional society with a focus on the causes and treatment of blood disorders. Experts from Rutgers Cancer Institute of New Jersey will be presenting a variety of key hematology data at the 62nd American Society of Hematology Annual Meeting. This includes 22 scheduled presentations, including 10 oral presentations examining several types of blood cancers including leukemia, lymphoma, and myeloma.

Exploring the Role of Tumor Suppressor Enhancers in the Development of T-cell Acute Lymphoblastic Leukemia

Researchers from Rutgers Cancer Institute of New Jersey identified a novel enhancer that interacts with a tumor suppressor gene and explored its involvement in normal T-cell development as well as in T-cell acute lymphoblastic leukemia (T-ALL).